Ubiquinone vs. Ubiquinol for In Vitro Fertilization

Recruiting in Palo Alto (17 mi)

Age: 18 - 65

Sex: Female

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Trio Fertility

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?The objective of this study is to determine if ubiquinol will result in improved reproductive outcomes in older women at a reduced oral dose compared to current standard treatment with ubiquinone.

Eligibility Criteria

Women aged >37 and <43 undergoing their first IVF cycle, with a history of infertility but normal reproductive health markers. They must have a BMI between 17.5 and 38, non-smokers, no significant medical conditions or ovarian issues that would affect egg retrieval, and partners with suitable semen for IVF.

Inclusion Criteria

My BMI is between 17.5 and 38.

I am a woman between 37 and 43 years old trying IVF for the first time.

My pelvic ultrasound showed no large cysts.

Exclusion Criteria

I have untreated Asherman's syndrome or unremoved endometrial polyps.

My ovaries cannot be used for egg collection.

My cancer is in the ovary, breast, uterus, pituitary, or hypothalamus.

I have had surgery on my ovary, such as for a cyst or tumor.

I have fluid in my fallopian tubes that shows on an ultrasound or special X-ray.

I have fibroids larger than 3 cm or any size if they are submucosal.

I have a history of serious health conditions like epilepsy or diabetes that required treatment in the last 3 years.

I currently smoke 5 or more cigarettes daily.

Participant Groups

The trial is testing if ubiquinol at a lower dose improves reproductive outcomes in older women compared to the standard treatment with ubiquinone during IVF cycles.

3Treatment groups

Experimental Treatment

Active Control

Group I: coQ10BExperimental Treatment1 Intervention

Eligible subjects will be receiving ubiquinol 100 mg prior to their IVF cycle.

Group II: coQ10 AExperimental Treatment1 Intervention

Eligible subjects will be receiving ubiquinone 200 mg prior to their in vitro fertilization (IVF) cycle.

Group III: ControlActive Control1 Intervention

Subjects are not receiving coQ10 supplementation.